BrainStorm Granted Additional Patent for NurOwn in Israel

Pharmaceutical Investing

BrainStorm Cell Therapeutics (NASDAQ:BCLI), a leader in developing innovative autologous cellular therapies for debilitating neurodegenerative diseases, today announced that the Israel Patent Office has granted an additional patent titled “Methods of Generating Mesenchymal Stem Cells which Secrete Neurotrophic Factors.” As quoted in the press release: The allowed claims cover the method of manufacturing the cells, …

BrainStorm Cell Therapeutics (NASDAQ:BCLI), a leader in developing innovative autologous cellular therapies for debilitating neurodegenerative diseases, today announced that the Israel Patent Office has granted an additional patent titled “Methods of Generating Mesenchymal Stem Cells which Secrete Neurotrophic Factors.”

As quoted in the press release:

The allowed claims cover the method of manufacturing the cells, the cells generated according to the method of manufacturing, and the use of the cells for preparation of a therapy for treating a disease (including a neurodegenerative disease, a neurological and an immune disease).

“Our intellectual property estate for NurOwn® technology platform continues to grow substantially as evidenced by this new patent granted by the Israel Patent Office which is a welcome addition to our IP portfolio. This patent covers NurOwn (MSC-NTF cells) and its manufacturing process developed by Brainstorm’s scientists as well as the use of NurOwn for the treatment of neurodegenerative diseases, an acute unmet need” commented BrainStorm’s CEO Chaim Lebovits. “Having an Israel patented product and manufacturing process will increase our ability to treat patients in desperate need of options for these debilitating diseases in Israel. We expect that additional patents owned or licensed exclusively by BrainStorm will be awarded this year and in future years, thereby broadening the utility of NurOwn in global markets across the world.”

Click here to read the full press release.

The Conversation (0)
×